Published: Mon, November 23, 2020
Economy | By

White House vaccine chief says first Americans could be vaccinated next month

White House vaccine chief says first Americans could be vaccinated next month

Dr. Moncef Slaoui, chief scientific adviser for Operation Warp Speed, listens as President Trump delivers remarks about coronavirus vaccine development in the Rose Garden on May 15.

Companies like Pfizer and Moderna have been leading the charge on vaccinations for COVID-19, with Pfizer previously claiming their COVID-19 vaccine is 90% effective.

Vaccines will be distributed based on each state's population, Dr Slaoui said.

He also said on Sunday that he anticipated life for Americans could return to normal as early as May.

A COVID-19 vaccine will reportedly be available to some Americans as early as December 11.

Many people are trying to get tested before the holiday on Thursday, leading to long lines in New York City and elsewhere. "What we do need is we need to get as many people as possible vaccinated".

"We're clearly involved now in a very, very hard surge here throughout the United States and even globally", Dr Anthony Fauci, the nation's top infectious disease expert, told NBC.


Pfizer on Friday said that it was moving ahead with its request of asking the United States regulators to grant emergency approval of its Covid-19 vaccine candidate, which has shown 95 per cent efficacy in a totality of two data sets released recently. "I really hope and look forward to seeing that the level of negative perception of the vaccine decreases and people's acceptance increases".

"The timeline of getting the doses into the vials and available for vaccination are going to be a graded process", Fauci began.

The highest-priority groups, which include health care workers, the elderly and people with underlying medical conditions, will get the vaccine first.

On 11 August, Russia became the first country in the world to register a coronavirus vaccine, dubbed Sputnik V. The vaccine, which is based on a human adenoviral vector platform, was developed by the Gamaleya Research Institute of Epidemiology and Microbiology and is now completing phase 3 clinical trials. Pfizer's application will be reviewed by an FDA advisory committed on December 10.

By the end of 2020, Moderna expects to produce approximately 20 million doses of its mRNA-1273 vaccine.

Formerly the head of the American company Moderna Stefan Bansel called the fair declared cost of the COVID-19 vaccine.

Like this: